Lexaria Bioscience Corp. (LEXX) Balance Sheet

20Y historyFree accessUpdated daily

The company's financial stability is increasingly fragile, as total assets have contracted from $10.0M in 2024Q3 to $6.5M in 2026Q2 while retained earnings have deepened to -$66.5M.

Annual statement

LEXX Balance Sheet

Lexaria Bioscience Corp. (LEXX) balance sheet — 20-year assets, liabilities & shareholders' equity history

Annual Quarterly

Metric	TTM	Aug'25	Aug'24	Aug'23	Aug'22	Aug'21	Aug'20	Aug'19	Aug'18	Aug'17	Aug'16	Aug'15	Aug'14	Oct'12	Oct'11	Oct'10	Oct'09	Oct'08	Oct'07	Oct'06	Oct'05

Total Current Assets	4.06M	3.47M	7.9M	2.2M	6.98M	12.44M	1.93M	1.82M	2.28M	2.8M	510.17K	674.73K	146.27K	182.33K	264.23K	730.32K	493.29K	330.54K	133.99K	1.3M	881.77K
Cash & Short-Term Investments	3.62M	1.97M	6.56M	1.48M	6.16M	11.75M	1.31M	1.35M	1.74M	2.53M	93.41K	260.07K	65.54K	27.53K	31.2K	494.44K	431.39K	239.66K	78.06K	1.29M	863.56K
Cash Only	3.48M	1.8M	6.5M	1.35M	5.81M	10.92M	1.29M	1.29M	1.73M	2.53M	93.41K	260.07K	65.54K	27.53K	31.2K	494.44K	431.39K	239.66K	78.06K	1.29M	863.56K
Short-Term Investments	142.1K	165.36K	55.81K	125.64K	347.33K	833.84K	19.32K	64.21K	10.15K	0	0	0	0	0	0	0	0	0	0	0	0
Accounts Receivable	49K	174K	154.48K	175.25K	201.78K	342.4K	313.93K	273.14K	265.75K	45.29K	131.08K	31.38K	79.22K	151.82K	290.94K	231.61K	57.22K	90.88K	15.51K	38.31K	0
Days Sales Outstanding	166.07	89.97	121.44	282.77	288.38	172.92	297.97	447.86	223.87	259.78	1.18K	779.11	26.35	50.49	78.21	74.56	57.61	78.61	6.28	55.24	-
Inventory	0	0	0	0	38.42K	29.65K	116.87K	127.4K	87.23K	67.17K	134.72K	167.99K	0	0	0	0	0	0	0	-17.62K	0
Days Inventory Outstanding	-	-	-	-	195.19	61.72	429.25	2.03K	1.26K	824.15	1.08K	2.05K	-	0	-	-	-	-	-	-	-
Other Current Assets	0	194.36K	0	0	0	0	0	0	0	0	0	0	1.51K	0	0	0	0	0	0	17.62K	1.73K
Total Non-Current Assets	716.46K	706.78K	969.8K	884.21K	856.41K	823.88K	902.28K	856.39K	147.78K	64.68K	56.47K	36.99K	3.43M	3.5M	4.08M	3.13M	2.93M	2.92M	3.66M	1.42M	218.74K
Property, Plant & Equipment	313.43K	334.94K	389.55K	421.59K	367.95K	459.25K	610.28K	591.26K	1.24K	1.86K	2.48K	0	3.43M	3.5M	4.04M	3.13M	2.93M	2.92M	3.66M	1.42M	218.74K
Fixed Asset Turnover	0.60x	2.11x	1.19x	0.54x	0.69x	1.57x	0.63x	0.38x	350.27x	34.29x	16.45x	-	0.32x	0.31x	0.34x	0.36x	0.12x	0.14x	0.25x	0.18x	0.09x
Goodwill	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
Intangible Assets	339.02K	307.82K	516.68K	462.63K	488.46K	364.62K	292K	265.13K	146.54K	62.83K	54K	36.99K	0	0	0	0	0	0	0	0	0
Long-Term Investments	128.03K	0	0	0	0	0	0	0	0	0	0	0	67.66K	0	0	0	0	0	0	0	0
Other Non-Current Assets	0	64.01K	63.58K	0	0	0	0	0	0	0	0	0	-67.66K	0	33.09K	0	0	0	0	0	0
Total Assets	4.78M	4.18M	8.87M	3.08M	7.83M	13.27M	2.83M	2.68M	2.43M	2.86M	566.64K	711.72K	3.57M	3.68M	4.34M	3.86M	3.42M	3.25M	3.8M	2.72M	1.1M
Asset Turnover	0.04x	0.17x	0.05x	0.07x	0.03x	0.05x	0.14x	0.08x	0.18x	0.02x	0.07x	0.02x	0.31x	0.30x	0.31x	0.29x	0.11x	0.13x	0.24x	0.09x	0.02x
Asset Growth %	-145.45%	-52.92%	187.54%	-60.63%	-40.95%	369.08%	5.72%	10.01%	-14.98%	404.76%	-20.38%	-80.08%	-2.98%	-15.13%	12.28%	13.06%	5.18%	-14.38%	39.59%	147.09%	-
Total Current Liabilities	383.41K	1.49M	1.1M	267.74K	194.04K	153.28K	225.92K	184.51K	43.64K	92.35K	433.88K	55.13K	1.42M	1.4M	1.08M	876.74K	1.14M	25.61K	400.98K	2.01M	11.18K
Accounts Payable	350.38K	1.37M	1.06M	225.04K	120.15K	104.89K	45.08K	31.46K	14.38K	32.57K	90.01K	33.07K	93.55K	136.27K	67.04K	322.31K	137.44K	0	2.69K	19.39K	1.69K
Days Payables Outstanding	-	183.18K	80.08K	2.61K	610.42	218.34	165.57	501.64	208.38	399.65	720.24	403.96	42.94	62.55	31.24	176.15	183.34	-	1.08	56.68	6.6
Short-Term Debt	0	0	0	0	0	7.93K	0	0	0	0	0	0	1.28M	1.28M	1.64M	754.5K	910.44K	788.79K	272.51K	0	0
Deferred Revenue (Current)	0	0	4.96K	0	0	0	44.26K	0	0	17.08K	12.5K	0	0	0	0	0	0	0	0	0	0
Other Current Liabilities	0	0	0	0	0	0	0	0	0	0	0	0	-452.68K	0	0	0	0	0	1.77K	320.69K	13.24K
Current Ratio	10.60x	2.32x	7.18x	8.22x	35.96x	81.18x	8.53x	9.86x	52.34x	30.27x	1.18x	12.24x	0.10x	0.13x	0.24x	0.83x	0.43x	12.91x	0.33x	0.64x	78.91x
Quick Ratio	10.60x	2.32x	7.18x	8.22x	35.76x	80.99x	8.01x	9.17x	50.34x	29.54x	0.87x	9.19x	0.10x	0.13x	0.24x	0.83x	0.43x	12.91x	0.33x	0.65x	78.91x
Cash Conversion Cycle	166.07	-	-	-	-126.85	16.3	561.65	1.98K	1.28K	684.28	1.53K	2.43K	-	-12.06	-	-	-	-	-	-	-
Total Non-Current Liabilities	53.68K	78.9K	109.32K	136.17K	7.4K	49.99K	120.06K	0	0	0	45K	0	59.24K	59.24K	59.24K	599.44K	75K	0	723.86K	0	0
Long-Term Debt	0	0	0	0	0	0	30.67K	0	0	0	45K	0	0	0	0	599.44K	75K	0	723.86K	0	0
Capital Lease Obligations	265.73K	78.9K	109.32K	136.17K	7.4K	49.99K	89.39K	0	0	0	0	0	0	0	0	0	0	0	0	0	0
Deferred Tax Liabilities	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
Other Non-Current Liabilities	0	0	0	0	0	0	0	0	0	0	0	0	59.24K	59.24K	59.24K	0	0	0	0	0	0
Total Liabilities	437.09K	1.57M	1.21M	403.91K	201.44K	203.26K	345.98K	184.51K	43.64K	92.35K	478.88K	55.13K	1.47M	1.46M	1.68M	1.48M	1.21M	788.18K	400.98K	2.01M	11.18K
Total Debt	86.71K	109.32K	137.37K	163.97K	49.99K	97.32K	156.1K	0	7.86K	42.69K	45K	0	1.28M	1.3M	1.35M	1.38M	897.29K	775.45K	50K	1.99M	0
Net Debt	-3.39M	-1.69M	-6.36M	-1.19M	-5.76M	-10.82M	-1.14M	-1.29M	-1.72M	-2.49M	-48.41K	-260.07K	1.21M	1.27M	1.32M	887.65K	465.9K	535.78K	-28.06K	701.46K	-863.56K
Debt / Equity	0.02x	0.04x	0.02x	0.06x	0.01x	0.01x	0.06x	-	0.00x	0.02x	0.51x	-	0.61x	0.58x	0.51x	0.58x	0.41x	0.31x	0.01x	2.82x	-
Debt / EBITDA	-0.01x	-	-	-	-	-	-	-	-	-	-	-	0.70x	4.86x	3.00x	12.44x	-	-	-	-	-
Net Debt / EBITDA	0.44x	-	-	-	-	-	-	-	-	-	-	-	0.67x	4.76x	2.93x	7.99x	-	-	-	-	-
Interest Coverage	-	-	-	-	-	-	-	-	-	-319.78x	-566.67x	-61.87x	-5.69x	-	-0.06x	-1.55x	-2.41x	-0.69x	-104.65x	-47.93x	-9.66x
Total Equity	4.34M	2.6M	7.66M	2.68M	7.63M	13.06M	2.48M	2.49M	2.39M	2.77M	87.76K	656.6K	2.1M	2.23M	2.66M	2.39M	2.21M	2.46M	3.39M	704.55K	1.09M
Equity Growth %	-141.92%	-66.02%	185.78%	-64.89%	-41.57%	426.28%	-0.34%	4.29%	-13.72%	3053.97%	-86.63%	-68.72%	-5.67%	-16.39%	11.42%	8.32%	-10.43%	-27.48%	381.85%	-35.32%	-
Book Value per Share	2.63	2.17	9.28	6.08	19.45	44.62	13.43	14.41	15.15	21.19	0.90	0.50	0.08	3.69	5.40	5.29	8.21	11.23	16.76	4.38	6.81
Total Shareholders' Equity	4.74M	2.99M	8.04M	3.04M	7.95M	13.27M	2.53M	2.38M	2.39M	3.01M	266.05K	772.41K	2.1M	2.23M	2.66M	2.39M	2.21M	2.46M	3.39M	704.55K	1.09M
Common Stock	24.79K	19.56K	15.81K	8.09K	5.95K	5.73K	3K	78.79K	75.53K	67.98K	51.29K	39.85K	16.43K	16.43K	16.43K	15.63K	12.85K	10.64K	23.76K	17.58K	16.88K
Retained Earnings	-68.5M	-63.46M	-51.56M	-45.76M	-39.1M	-31.83M	-27.8M	-23.87M	-19.77M	-13.17M	-11.3M	-10.09M	-5.06M	-4.93M	-4.46M	-4.46M	-3.85M	-3.2M	-1.64M	-583.98K	-75.72K
Treasury Stock	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
Accumulated OCI	-46.47K	-70.33K	-19.82K	0	0	0	0	0	-14.25K	0	0	0	-35.2K	0	0	0	0	0	0	0	0
Minority Interest	-393.97K	-386.94K	-377.35K	-364.04K	-316.41K	-202.09K	-42.94K	107.67K	0	-238.48K	-178.29K	-115.81K	0	0	0	0	0	0	0	0	0

Key Metrics

Growth RegimeContracting

ProfitabilityNegative

Balance SheetVulnerable

Cash FlowBurning

Top Statement Risk

Imminent liquidity and dilution

Verified Source

Metrics are mathematically derived from official filings.

SEC 10-K (2026Q2)

Asset Base Erosion Signals Instability

As reported in financial statements, Lexaria's total assets have declined from a peak of $10.0M in 2024Q3 to $6.5M in 2026Q2, reflecting a consistent contraction in the company's resource base as it consumes capital to fund ongoing research and development without achieving commercial scale.

The downward trend in total assets suggests that the company is struggling to replenish its balance sheet through organic growth or successful licensing milestones. This trajectory implies that the firm is becoming increasingly reliant on external capital markets to maintain its operational footprint.

Cash Runway Constraints Demand Attention

Based on recent SEC filings, Lexaria's cash position has fluctuated significantly, dropping to $1.8M in 2025Q4 before recovering to $5.1M in 2026Q2, yet this volatility highlights a precarious reliance on periodic financing rounds to sustain its high-burn clinical trial operations.

While the current ratio of 26.88 appears superficially strong, it is heavily skewed by the timing of cash inflows from equity raises rather than operational liquidity. Investors should monitor the burn rate closely, as the lack of recurring revenue makes the company highly sensitive to capital market conditions.

Dilution Risk Remains Persistent Threat

According to historical balance sheet data, Lexaria's equity base has been subject to significant volatility, with retained earnings deepening to -$66.5M as of 2026Q2, indicating that the company's primary method of funding its operations is through the continuous issuance of equity to shareholders.

The persistent accumulation of negative retained earnings underscores the difficulty the company faces in reaching a self-sustaining business model. This reliance on equity financing suggests that existing shareholders may face ongoing dilution as the firm seeks to bridge the gap between its current R&D phase and potential commercialization.

Intangible Asset Valuation Risks Loom

As evidenced by the reported $318.1K in goodwill as of 2026Q2, there is a non-trivial risk that these intangible assets may require impairment if the company's clinical trials fail to yield the expected commercial outcomes for its proprietary drug delivery platform.

The presence of goodwill on the balance sheet warrants further investigation, as it may represent historical acquisition costs that no longer align with the current market valuation of the technology. If the company's patent portfolio fails to generate meaningful licensing revenue, these assets could become a source of future write-downs.

LEXX — Frequently Asked Questions

Quick answers to the most common questions about buying LEXX stock.

What are the total assets of Lexaria Bioscience Corp. (LEXX)?

As of 2025, Lexaria Bioscience Corp. (LEXX) had total assets of $4.2M including $3.5M in current assets.

How much debt does Lexaria Bioscience Corp. (LEXX) have?

Lexaria Bioscience Corp. (LEXX) carries total debt of $0.1M, offset by $2.0M in cash and short-term investments. Comparing total debt to cash helps evaluate the company's debt burden and net leverage.

What is the book value or shareholders' equity of Lexaria Bioscience Corp.?

Lexaria Bioscience Corp. (LEXX) has total shareholders' equity (book value) of $3.0M ($2.17 book value per share). Book value represents the net worth of the company belonging to common stock holders.

What is Lexaria Bioscience Corp.'s current ratio and liquidity?

Lexaria Bioscience Corp. (LEXX) reported a current ratio of 2.32x. A current ratio above 1.0x indicates that the company has more current assets than current liabilities, suggesting sufficient short-term liquidity.